58584-95-5Relevant academic research and scientific papers
In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3- carbonitriles as JAK2 kinase inhibitors
Wang, Tao,Ioannidis, Stephanos,Almeida, Lynsie,Block, Michael H.,Davies, Audrey M.,Lamb, Michelle L.,Scott, David A.,Su, Mei,Zhang, Hai-Jun,Alimzhanov, Marat,Bebernitz, Geraldine,Bell, Kirsten,Zinda, Michael
, p. 2958 - 2961 (2011/06/26)
Synthesis and biological evaluation of a series of 6-aminopyrazolyl- pyridine-3-carbonitriles as JAK2 kinase inhibitors was reported. Biochemical screening, followed by profile optimization, resulted in JAK2 inhibitors exhibiting good kinase selectivity, pharmacokinetic properties, physical properties and pharmacodynamic effects.
PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
-
Page/Page column 110, (2008/06/13)
This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na+/H+ exchanger
Laeckmann, Didier,Rogister, Fran?oise,Dejardin, Jean-Victor,Prosperi-Meys, Christelle,Géczy, Joseph,Delarge, Jacques,Masereel, Bernard
, p. 1793 - 1804 (2007/10/03)
Pyridine and benzene bioisosteres of amiloride were synthesized and evaluated for their inhibitory potency against the sodium-hydrogen exchanger (NHE) involved in intracellular pH regulation. The inhibition of NHE was determined by using the platelet swelling assay (PSA) in which the swelling of human platelets was induced by their incubation in an acid buffer (pH 6.7). Additionally, the inhibitory potency of the most active compounds was assessed by measuring the inhibition of the EIPA-sensitive 22Na+ uptake (UIA) by human platelets after intracellular acidosis. The results indicated that several benzene derivatives and compounds bearing an carbonylguanidine moiety in the meta position of the pyridine nitrogen were much more potent than amiloride (PSA:IC50=43.5 μM; UIA:IC50=100.1 μM), but less than EIPA, a pyrazine NHE inhibitor (PSA:IC50=0.08 μM; UIA:IC50=0.5 μM). In both biological assays (2-amino-5-bromo-pyridine-3-carbonyl)guanidine (32) was the most active molecule (PSA:IC50=0.8 μM, UIA:IC50=0.8 μM). Our investigations demonstrated that the replacement of the pyrazine ring of amiloride by a pyridine or a phenyl ring improved the NHE inhibitory potency (phenyl >pyridine >pyrazine).
